Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-21
DOI
10.3389/fphar.2019.00697
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- (2019) Andrew D. Zelenetz et al. BLOOD
- Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. BLOOD
- ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma
- (2018) Yujie Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
- (2018) Steven Coutre et al. BLOOD
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic inhibition of BCL-2 and related family members
- (2017) Michelle A. Levy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
- (2017) Apurvasena Parikh et al. LEUKEMIA & LYMPHOMA
- Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
- (2017) Lloyd T. Lam et al. MOLECULAR CANCER THERAPEUTICS
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
- (2017) Akane Inoue-Yamauchi et al. Nature Communications
- Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
- (2017) Pin-Fang He et al. Oncotarget
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- Apoptosis therapy: driving cancers down the road to ruin
- (2013) Douglas R. Green et al. NATURE MEDICINE
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Tumor Lysis Syndrome
- (2011) Scott C. Howard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now